ESUR Guidelines on Contrast Agents
European Society of Urogenital Radiology
The Contrast Media Safety Committee is proud to present the 10th version of its Contrast Agent Guidelines. We started in 1994 and we have on average updated the booklet every 2 to 3 years. Over the years, more than 200,000 copies of the booklet have been printed and it has been translated into many languages. Although the contrast agents in current use have been on the market for many years, minor changes occur in their adverse reaction pattern and new observations are reported.

The 10th version of the Guidelines includes updated sections on acute adverse reactions, gadolinium contrast agents and other gadolinium issues, post contrast acute kidney injury (PC-AKI) and myeloma and contrast media. The CMSC has decided to regularize its use of the terms ‘contrast agent’ and ‘contrast medium’ and there is a brief section on terminology at the start of the Guidelines.

We hope that you like the new version, that it is helpful in your practice and that it will benefit all our patients. Comments and questions are welcome at esursecretary@esur.org

Contrast Media Safety Committee
March 2018
Henrik S. Thomsen, Chairman

**NOTE:** CMSC guidelines are based on evidence in the literature whenever possible. Where there is insufficient published evidence, guidelines are based on clinical consensus within the Committee.

Some CMSC guidelines may differ from the Summary of Product Characteristics (SPC, label), and/or guidelines drawn up by national and other radiological bodies.

**LEGAL NOTICE:** The Committee and authors of the 10.0 contrast media guidelines claim no responsibility for the content of the translated versions of the guidelines.
QUICK GUIDE TO THE CMSC CONTRAST AGENT GUIDELINES, VERSION 10

Terminology: Contrast agents and contrast media

SECTION A: GENERAL ADVERSE REACTIONS

Includes material on:
• Acute adverse reactions to iodine- and gadolinium-based contrast agents.
• Management of acute adverse reactions to iodine- and gadolinium-based and ultrasound contrast agents.
• Late adverse reactions.
• Thyrotoxicosis.
• Nephrogenic systemic fibrosis (NSF).

SECTION B: RENAL ADVERSE REACTIONS (POST CONTRAST ACUTE KIDNEY INJURY, PC-AKI)

Includes material on:
• Measurement of renal function.
• Renal adverse reactions to iodine- and gadolinium-based contrast agents.
• Metformin.

SECTION C: MISCELLANEOUS

All other topics for which the Committee has prepared guidelines, including:
• Pediatric use of contrast agents.
• Contrast medium extravasation.
• Pregnancy and lactation.
• Ultrasound contrast agents.
• Barium contrast media.
• Off-label use of contrast agents.
# CONTENTS

## TERMINOLOGY: CONTRAST AGENTS AND CONTRAST MEDIA

### A. GENERAL ADVERSE REACTIONS

#### A.1. ACUTE ADVERSE REACTIONS
- A.1.1. Acute adverse reactions to iodine- and gadolinium-based contrast agents
- A.1.2. Management of acute adverse reactions
- A.1.3. Warming iodine-based contrast medium before administration
- A.1.4. Extravascular administration of an iodine-based contrast medium
- A.1.5. Fasting before administration of contrast agents

#### A.2. LATE ADVERSE REACTIONS

#### A.3. VERY LATE ADVERSE REACTIONS
- A.3.1. Very late adverse reactions to iodine-based contrast media: thyrotoxicosis
- A.3.2. Very late adverse reactions to gadolinium-based contrast agents: nephrogenic systemic fibrosis (NSF)

### B. RENAL ADVERSE REACTIONS (POST-CONTRAST ACUTE KIDNEY INJURY, PC-AKI)

#### B.1. MEASUREMENT OF RENAL FUNCTION

#### B.2. RENAL ADVERSE REACTIONS TO IODINE-BASED CONTRAST MEDIA
- B.2.1. Time of Referral
- B.2.2. Before the Examination
- B.2.3. Time of examination
- B.2.4. After the Examination
- B.2.5. Multiple myeloma patients

#### B.3. RENAL ADVERSE REACTIONS TO GADOLINIUM-BASED CONTRAST MEDIA

#### B.4. PATIENTS WITH DIABETES MELLITUS TAKING METFORMIN
- B.4.1. Iodine-based contrast media
- B.4.2. Gadolinium-based contrast media

#### B.5. DIALYSIS AND CONTRAST MEDIUM ADMINISTRATION

#### B.6. CAN IODINE- AND GADOLINIUM-BASED CONTRAST AGENTS SAFELY BE GIVEN ON THE SAME DAY FOR ROUTINE EXAMINATIONS?

#### B.7. HOW LONG SHOULD THERE BE BETWEEN TWO IODINE-BASED CONTRAST MEDIUM INJECTIONS FOR ROUTINE EXAMINATIONS?

#### B.8. HOW LONG SHOULD THERE BE BETWEEN TWO GADOLINIUM-BASED CONTRAST AGENT INJECTIONS FOR ROUTINE EXAMINATIONS?
Terminology: Contrast agents and contrast media

A contrast agent is a substance which alters the contrast in images produced by any method. It is a general term which can be used for X-ray, MR and ultrasound contrast compounds.

A contrast medium is a substance which alters the contrast in X-ray images by altering transmission of the X-ray beam. This term should be reserved for X-ray contrast compounds, e.g. iodine-based, barium, air and carbon dioxide.
A. GENERAL ADVERSE REACTIONS

A.1. ACUTE ADVERSE REACTIONS

Definition: An adverse reaction which occurs within 1 hour of contrast agent injection.

The same acute adverse reactions are seen after iodine- and gadolinium-based contrast agents and after ultrasound contrast agents. The incidence is highest after iodine-based contrast media and lowest after ultrasound agents.

Classification

Acute reactions are either allergy-like, hypersensitivity reactions or chemotoxic responses. Allergy-like reactions may or may not be true IgE mediated allergy.

<table>
<thead>
<tr>
<th>Hypersensitivity/Allergy-like</th>
<th>Grade (Ring and Messmer classification)</th>
<th>Chemotoxic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild</td>
<td>Grade 1</td>
<td>Nausea/mild vomiting</td>
</tr>
<tr>
<td></td>
<td>Grade 1</td>
<td>Warmth/chills</td>
</tr>
<tr>
<td></td>
<td>Grade 1</td>
<td>Anxiety</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vasovagal reaction which resolves spontaneously</td>
</tr>
<tr>
<td>Moderate</td>
<td>Grade 1</td>
<td>Vasovagal reaction</td>
</tr>
<tr>
<td></td>
<td>Grade 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Grade 2</td>
<td></td>
</tr>
<tr>
<td>Severe</td>
<td>Grade 3</td>
<td>Arrythmia</td>
</tr>
<tr>
<td></td>
<td>Grade 4</td>
<td>Convulsion</td>
</tr>
<tr>
<td></td>
<td>Grade 4</td>
<td></td>
</tr>
</tbody>
</table>

Note:

- Be aware that what at first appears to be a mild reaction may develop into a more serious reaction.
- Not all symptoms experienced by patients in the hour after contrast agent injections are adverse reactions to the contrast agent.
- Patient anxiety may cause symptoms after contrast agent administration (Lalli effect).
- When a new contrast agent is first introduced to a department, adverse effects tend to be over-reported (Weber effect).
### A.1.1. Acute adverse reactions to iodine- and gadolinium-based contrast agents

**Note:** Retrospective studies of the incidence of acute adverse reactions suffer from considerable under-reporting and are therefore unreliable.

#### Risk factors for acute reactions

<table>
<thead>
<tr>
<th>Patient related</th>
<th>Patients with a history of:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• Previous moderate or severe acute reaction (see classification above) to an iodine- or gadolinium-based contrast agent.</td>
</tr>
<tr>
<td></td>
<td>• Asthma requiring medical treatment.</td>
</tr>
<tr>
<td></td>
<td>• Atopy requiring medical treatment.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Contrast medium related</th>
</tr>
</thead>
<tbody>
<tr>
<td>a) Iodine-based:</td>
</tr>
<tr>
<td>• High-osmolality ionic contrast media.</td>
</tr>
<tr>
<td>• There is no difference in the incidence of acute reactions between the non-ionic low-osmolar contrast agents and the non-ionic iso-osmolar contrast agents.</td>
</tr>
<tr>
<td>• There is no difference in the incidence of acute adverse events among the non-ionic low-osmolar agents.</td>
</tr>
<tr>
<td>b) Gadolinium-based:</td>
</tr>
<tr>
<td>• The risk of a reaction is not related to the osmolality of the contrast agent: the low doses used make the osmolar load very small.</td>
</tr>
<tr>
<td>• There is no difference in the incidence of acute adverse reactions among the gadolinium-based extracellular agents.</td>
</tr>
</tbody>
</table>

### To reduce the risk of an acute reaction to iodine- and gadolinium-based agents

<table>
<thead>
<tr>
<th>For all patients</th>
<th>Use a non-ionic iodine-based contrast medium.</th>
</tr>
</thead>
<tbody>
<tr>
<td>For patients at increased risk of reaction (see risk factors above)</td>
<td>• Consider an <strong>alternative test</strong> not requiring a contrast agent of similar class.</td>
</tr>
<tr>
<td></td>
<td>• For previous contrast agent reactors: use a different contrast agent, preferably after consultation with a specialist in drug allergy.</td>
</tr>
<tr>
<td></td>
<td>• Premedication is not recommended because there is not good evidence of its effectiveness</td>
</tr>
</tbody>
</table>

### Be prepared for an acute reaction

<table>
<thead>
<tr>
<th>For all patients</th>
<th>Have the drugs and equipment for resuscitation readily available (see A.1.2.1.).</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• Keep the patient in a medical environment for 30 minutes after contrast agent injection.</td>
</tr>
</tbody>
</table>
A.1.2. Management of acute adverse reactions

The management is the same for acute adverse reactions after iodine-and gadolinium-based and ultrasound contrast agents.

A.1.2.1. Be prepared to treat acute adverse reactions

First line emergency drugs and equipment which should be in the examination room:

- Oxygen
- Adrenaline 1:1,000
- Antihistamine H1 - suitable for injection
- Atropine
- β2-agonist metered dose inhaler
- I.V. fluids - normal saline or Ringer’s solution
- Anti-convulsive drugs (diazepam)
- Sphygmomanometer
- One-way mouth ‘breather’ apparatus

- Resuscitation trolley should be available in the department.
- Emergency numbers for the hospital resuscitation team should be in the examination room.
- Medical and technical staff should receive regular education in the management of acute adverse reactions and in resuscitation technique.
- Equipment for collecting blood for tryptase and histamine measurement should be readily available.
- Keep the patient in a medical environment for 30 minutes after contrast agent injection.

A.1.2.2. Simple guidelines for first line treatment of acute reactions to all contrast agents

When an acute reaction occurs, check for the following:
- Skin erythema, urticaria (undress the patient to inspect the whole body).
- Nausea, vomiting.
- Decreased blood pressure, abnormal heart rate.
- Dyspnea, bronchospasm (requires auscultation for reliable diagnosis).
Nausea/vomiting

**Transient:** supportive treatment.

**Severe, protracted:** appropriate antiemetic drugs should be considered.

**Note:** severe vomiting may occur during anaphylaxis.

Urticaria

**Scattered, transient:** supportive treatment including observation.

**Scattered, protracted or generalized or angioedema:** appropriate H1-antihistamine should be given intramuscularly or intravenously. Drowsiness and/or hypotension may occur. After administration of anisthistamines, the patient may no longer be insured to drive a car or operate machinery.

Bronchospasm

1. Oxygen by mask (6-10 l/min).
2. $\beta_2$-agonist metered dose inhaler (2-3 deep inhalations).
3. Adrenaline

**Normal blood pressure**

Intramuscular: 1:1,000, 0.1-0.3 ml (0.1-0.3 mg) [use smaller dose in patients with coronary artery disease or elderly patients].

In pediatric patients: 50 % of adult dose to pediatric patients between 6 and 12 years old and 25 % of adult dose to pediatric patients below 6 years old - repeat as needed.

**Decreased blood pressure**

Intramuscular: 1:1,000, 0.5 ml (0.5 mg).

In pediatric patients: 6-12 years: 0.3 ml (0.3 mg) intramuscularly

< 6 years: 0.15 ml (0.15 mg) intramuscularly

Laryngeal edema

1. Oxygen by mask (6-10 l/min).
2. Intramuscular adrenaline (1:1,000), 0.5 ml (0.5 mg) for adults - repeat as needed.
   
   In pediatric patients: 6-12 years: 0.3 ml (0.3 mg) intramuscularly
   
   < 6 years: 0.15 ml (0.15 mg) intramuscularly

Hypotension

**Isolated hypotension**

1. Elevate patient’s legs.
2. Oxygen by mask (6-10 l/min).
3. Intravenous fluid: rapidly, normal saline or Ringer’s solution up to 2 litres.
4. If unresponsive: adrenaline: 1:1,000, 0.5 ml (0.5 mg) intramuscularly - repeat as needed.
   
   In pediatric patients: 6-12 years: 0.3 ml (0.3 mg) intramuscularly
   
   < 6 years: 0.15 ml (0.15 mg) intramuscularly
Vasovagal reaction (hypotension and bradycardia)
1. Elevate patient’s legs.
2. Oxygen by mask (6-10 l/min).
3. Atropine 0.6-1.0 mg intravenously - repeat if necessary after 3-5 min, to 3 mg total (0.04 mg/kg) in adults. In pediatric patients give 0.02 mg/kg intravenously (max 0.6 mg per dose) - repeat if necessary to 2 mg total.
4. Intravenous fluids: rapidly, normal saline or Ringer’s solution, up to 2 litres.
5. If the patient does not respond to these measures, treat as for anaphylaxis.

Generalized anaphylactoid reaction
1. Call for resuscitation team.
2. Suction airway as needed.
3. Elevate patient’s legs if hypotensive.
4. Oxygen by mask (6-10 l/min).
5. Intramuscular adrenaline (1:1,000), 0.5 ml (0.5 mg) in adults - repeat as needed.
   In pediatric patients: 6-12 years: 0.3 ml (0.3 mg) intramuscularly<br>   < 6 years: 0.15 ml (0.15 mg) intramuscularly
6. Intravenous fluids (e.g. normal saline, Ringer’s solution) up to 2 litres.
7. H1-blocker e.g. diphenhydramine 25-50 mg intravenous.

A.1.2.3. After a moderate or severe acute adverse reaction to a contrast agent

Test for evidence of allergy
- Take blood samples for estimation of histamine and tryptase at 1 and 2 hours after contrast agent administration and at 24 hours if the patient is still in the hospital.
- 1 to 6 months after the reaction the patient should be referred to a specialist in drug allergy to have skin testing. Prick and intradermal tests should be used to check for evidence of true allergy to the contrast agent and for evidence of cross-reactivity to other contrast agents.
- An example of a suitable letter for the patient to take to the allergy consultation can be found in section D of these guidelines.
Record the reaction
- Record the contrast agent name and dose and the details of the reaction and its treatment in the patient’s records.
- Record the information about the reaction (see above) in the hospital adverse events register.
- If the reaction is severe or unusual, report it to the national pharmacovigilance authority.

A.1.2.4. Review of treatment protocols
Radiologists and their staff should review treatment protocols regularly (e.g. at 12 monthly intervals), so that each can accomplish their role efficiently. Knowledge, training, and preparation are crucial for guaranteeing appropriate and effective treatment if there is an adverse contrast related event.

A.1.3. Warming iodine-based contrast medium before administration
- Appears to make the patient more comfortable, based on clinical observation.
- Reduces viscosity and may reduce the risk of contrast medium extravasation.
- May reduce the rate of general adverse events, but data on this is limited.
- Is widely regarded as best practice.

A.1.4. Extravascular administration of an iodine-based contrast medium
- When absorption or leakage into the circulation is possible, take the same precautions as for intravascular administration.

A.1.5. Fasting before administration of contrast agents
Fasting before intravenous administration of contrast agents dates from the time when high-osmolar iodine-based contrast media were used and many patients vomited. Fasting is not recommended before administration of low- or iso-osmolar non-ionic iodine-based contrast media or of gadolinium-based agents.
### A.2. LATE ADVERSE REACTIONS

**Definition**
A late adverse reaction to intravascular iodine-based contrast medium is defined as a reaction which occurs 1 h to 1 week after contrast medium injection.

**Reactions**
- **Skin reactions**
  - Similar in type to other drug-induced eruptions occur. Maculopapular rashes, erythema, swelling and pruritus are most common. Most skin reactions are mild to moderate and self-limiting.
  - A variety of late symptoms (e.g., nausea, vomiting, headache, musculoskeletal pains, fever) have been described following contrast medium, but many are not related to the contrast medium.

**Risk factors for skin reactions**
- Previous late contrast medium reaction
- Interleukin-2 treatment
- Use of non-ionic dimers

**Management**
Symptomatic and similar to the management of other drug-induced skin reactions e.g. antihistamines, topical steroids and emollients.

**Recommendations**
Patients who have had a previous contrast medium reaction, or who are on interleukin-2 treatment should be advised that a late skin reaction is possible and that they should contact a doctor if they have a problem.

- Patch and delayed reading intradermal tests may be useful to confirm a late skin reaction to contrast medium and to study cross-reactivity patterns with other agents.
- To reduce the risk of repeat reaction, use a contrast medium other than that which precipitated the first reaction. Avoid agents which have shown cross-reactivity on skin testing.
- Drug prophylaxis is generally not recommended.

**Note:** Late skin reactions of the type which occur after iodine-based contrast media have not been described after gadolinium-based and ultrasound contrast media.
A.3. **VERY LATE ADVERSE REACTIONS**

**Definition:** an adverse reaction which usually occurs more than 1 week after contrast agent injection.

<table>
<thead>
<tr>
<th>Type of reaction</th>
<th>Iodine-based contrast media</th>
<th>Gadolinium-based contrast agents</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• Thyrotoxicosis</td>
<td>• Nephrogenic systemic fibrosis</td>
</tr>
</tbody>
</table>

**A.3.1. Very late adverse reactions to iodine-based contrast media: thyrotoxicosis**

**At risk**
- Patients with untreated Graves’ disease.
- Patients with multinodular goiter and thyroid autonomy, especially if they are elderly and/or live in an area of dietary iodine deficiency.

**Not at risk**
- Patients with normal thyroid function.

**Recommendations**
- **Iodine-based contrast media should not be given to patients with manifest hyperthyroidism.**
  - In patients suspected of being at risk of thyrotoxicosis, TSH measurement may be helpful.
  - In selected high-risk patients, prophylactic treatment may be given by an endocrinologist.
  - Patients at risk should be closely monitored by endocrinologists after iodine-based contrast medium injection.
  - Intravenous cholangiographic contrast media should not be given to patients at risk.
A.3.2. Very late adverse reactions to gadolinium-based contrast agents: nephrogenic systemic fibrosis (NSF)

**Diagnosis**
A diagnosis of nephrogenic systemic fibrosis (NSF) should only be made if the Yale NSF Registry clinical and histopathological criteria are met (J Am Acad Dermatol 2011; 65: 1095-1106). The association between nephrogenic systemic fibrosis (NSF) and gadolinium-based contrast agents was recognized in 2006.

**Clinical features**
*Onset* can be from the day of exposure for up to 2-3 months. Rarely, it can occur years after exposure.

*Early changes* are pain, pruritus, and swelling and erythema of the skin, which usually start in the legs.

*Later changes* include fibrotic thickening of the skin and subcutaneous tissues and limb contractures may occur. Fibrosis of internal organs, e.g. muscle, diaphragm, heart, liver, lungs may also occur. There may be *death* if involvement of internal organs is severe.

**RISK FACTORS**

**Patient related**
- Reduced renal function, particularly if eGFR < 15 ml/min/1.73 m2.
- Patients on dialysis.

**Contrast agent related**
- Gadodiamide was responsible for most reported NSF cases.
- NSF also occurred after gadopentetate dimeglumine and gadoversetamide.
- Risk increases with increasing contrast agent dose, but NSF may occur after a single dose.

**Estimated incidence in patients with severe renal failure**
- 3-18 % after gadodiamide.
- 0.1-1 % after gadopentetate dimeglumine.
### GADOLINIUM-BASED CONTRAST AGENTS:
Risk classification (based on laboratory data) and recommendations

#### Highest risk of NSF

| Contrast agents | Gadodiamide (Omniscan®)  
**Ligand**: Non-ionic linear chelate (DTPA-BMA)  
Gadopentetate dimeglumine (Magnevist®)  
**Ligand**: Ionic linear chelate (DTPA)  
Gadoversetamide (Optimark®)  
**Ligand**: Non-ionic linear chelate (DTPA-BMEA) |
|-----------------|---|
| **Recommendations** | • European Medicines Agency (EMA) has suspended intravenous use of all high-risk agents (Omniscan®, Magnevist®) and the Marketing Authorization Holder has withdrawn Optimark® from the European market.  
• EMA states that Magnevist® may be used for arthrography.  
• CMSC supports these recommendations. |

#### Intermediate risk of NSF

| Contrast agents | Gadobenate dimeglumine (Multihance®)  
**Ligand**: Ionic linear chelate (BOPTA)  
**Special feature**: It is a combined extracellular and liver specific agent with 2-3% albumin binding. In man ~4% is excreted via the liver.  
Gadoxetate disodium (Primovist®, Eovist®)  
**Ligand**: Ionic linear chelate (EOB-DTPA) |
|-----------------|---|
| **Recommendations** | • EMA states that intermediate risk agents (Multihance®, Primovist®) are approved for hepato-biliary imaging only.  
• CMSC supports this recommendation. |
<table>
<thead>
<tr>
<th>Lowest risk of NSF</th>
<th>Contrast agents</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Gadobutrol (Gadovist®, Gadavist®)</td>
<td>• These agents should be used with CAUTION in patients with GFR &lt; 30 ml/min. There should be at least 7 days between two injections.</td>
</tr>
<tr>
<td></td>
<td>Gadoterate meglumine (Dotarem®, Magnescope® plus generic products)</td>
<td>• Pregnant women: these agents can be used to give essential diagnostic information.</td>
</tr>
<tr>
<td></td>
<td>Gadoteridol (Prohance®)</td>
<td>• Lactating women: discarding the breast milk in the 24 hours after contrast medium is not considered necessary, but the patient can discuss with the doctor whether she wishes to do this.</td>
</tr>
<tr>
<td></td>
<td>Ligand: Non-ionic cyclic chelate (BT-DO3A)</td>
<td>• Laboratory testing of renal function (eGFR) is not mandatory.</td>
</tr>
<tr>
<td></td>
<td>Ligand: Ionic cyclic chelate (DOTA)</td>
<td>Recommendations for all patients</td>
</tr>
<tr>
<td></td>
<td>Ligand: Non-ionic cyclic chelate (HP-DO3A)</td>
<td>Never deny a patient a clinically well-indicated enhanced MR-examination.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>In all patients use the smallest amount of contrast medium necessary for a diagnostic result.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Always record the name and dose of the contrast agent used in the patient records.</td>
</tr>
</tbody>
</table>
B. RENAL ADVERSE REACTIONS
(POST-CONTRAST ACUTE KIDNEY INJURY, PC-AKI)

Definitions:

Post-contrast acute kidney injury (PC_AKI) is defined as an increase in serum creatinine > 0.3 mg/dl (or > 26.5 µmol/l), or > 1.5 times baseline, within 48-72 hours of intravascular administration of a contrast agent.

Intra-arterial injection with first pass renal exposure indicates that contrast agent reaches the renal arteries in a relatively undiluted form, e.g. injection into the left heart, thoracic and suprarenal abdominal aorta or the renal arteries.

Intra-arterial injection with second pass renal exposure indicates that contrast agent reaches the renal arteries after dilution either in the pulmonary or peripheral circulation, e.g. injection into the right heart, pulmonary artery, carotid, subclavian, coronary, mesenteric or infra-renal arteries.

B.1. MEASUREMENT OF RENAL FUNCTION

- Estimated glomerular filtration rate (eGFR), calculated from the serum creatinine, is the recommended method to estimate renal function before contrast agent administration.

- In adults ≥ 18 years the CKD-EPI formula is recommended to calculate eGFR.

\[
eGFR \text{ (ml/min/1.73 m²)} =
\begin{align*}
\text{Female } sCr & \leq 62 \text{ µmol/l: } 144 \times (sCr / 62)^{-0.329} \times 0.993^{\text{Age}} \\
\text{Female } sCr > 62 \text{ µmol/l: } 144 \times (sCr / 62)^{-1.209} \times 0.993^{\text{Age}} \\
\text{Male } sCr \leq 80 \text{ µmol/l: } 141 \times (sCr / 80)^{-0.411} \times 0.993^{\text{Age}} \\
\text{Male } sCr > 80 \text{ µmol/l: } 141 \times (sCr / 80)^{-1.209} \times 0.993^{\text{Age}}
\end{align*}
\]

(sCr in µmol/l; age in years)

\text{All equations } \times 1.159 \text{ if African American race.}

- In children, the revised Schwartz formula is recommended to calculate eGFR

\[
eGFR \text{ (ml/min/1.73 m²)} = 36.5 \times \text{length} / sCr
\]
\text{(sCr in µmol/l; length in cm)}

\text{Note: Neither serum nor plasma creatinine is an ideal indicator of renal function and may miss decreased renal function.}
### B.2. RENAL ADVERSE REACTIONS TO IODINE-BASED CONTRAST MEDIA

**RISK FACTORS FOR PC-AKI**

| Patient related | eGFR less than 45 ml/min/1.73 m² before intra-arterial contrast medium administration with first pass renal exposure or in ICU patients.  
|                 | eGFR less than 30 ml/min/1.73 m² before intravenous contrast medium or intra-arterial contrast medium administration with second pass renal exposure.  
|                 | Known or suspected acute renal failure.  
| Procedure related | Intra-arterial contrast medium administration with first pass renal exposure.  
|                 | Large doses of contrast medium given intra-arterially with first pass renal exposure.  
|                 | High-osmolality contrast media.  
|                 | Multiple contrast medium injections within 48-72 hours. |

### B.2.1. Time of Referral

**ELECTIVE EXAMINATION**

**MEASUREMENT OF RENAL FUNCTION**

- **Measure eGFR before administering intravascular iodine-based contrast medium**
  - Either (a) In all patients  
  - or (b) In patients who have a history of  
    - Renal disease (eGFR < 60 ml/min/1.73 m²)  
    - Kidney surgery  
    - Proteinuria  
    - Hypertension  
    - Hyperuricemia  
    - Diabetes mellitus  

- **Timing of eGFR measurement**
  - Within 7 days before contrast medium administration in patients with an acute disease, an acute deterioration of a chronic disease or who are hospital inpatients.  
  - Within 3 months before contrast medium administration in all other patients.
Identify at-risk patients (see above) if possible:

- Determine eGFR if the procedure can be deferred until the result is available without harm to the patient.
- If eGFR cannot be obtained, follow the protocols for patients with eGFR less than 45 ml/min/1.73 m² for intra-arterial administration with first pass renal exposure and eGFR less than 30 ml/min/1.73 m² for intravenous administration and intra-arterial administration with second pass renal exposure as closely as clinical circumstances permit.

### B.2.2. Before the Examination

**EMERGENCY EXAMINATION**

- Identify at-risk patients (see above) if possible:
  - Determine eGFR if the procedure can be deferred until the result is available without harm to the patient.
  - If eGFR cannot be obtained, follow the protocols for patients with eGFR less than 45 ml/min/1.73 m² for intra-arterial administration with first pass renal exposure and eGFR less than 30 ml/min/1.73 m² for intravenous administration and intra-arterial administration with second pass renal exposure as closely as clinical circumstances permit.

**ELECTIVE EXAMINATION**

**At-risk patients (see above)**

- Consider an alternative imaging method not using iodine-based contrast media.
- Intravenous saline and bicarbonate protocols have similar efficacy for preventive hydration.
- For intravenous contrast medium and intra-arterial contrast medium administration with second pass renal exposure hydrate the patient *either* (a) with intravenous sodium bicarbonate 1.4 % (or 154 mmol/l in dextrose 5 % water): 3 ml/kg/h for 1 hour before contrast medium or (b) with intravenous saline 0.9 % 1 ml/kg/hr for 3-4 hours before and 4-6 hours after contrast medium.
- For intra-arterial contrast medium administration with first pass renal exposure hydrate the patient *either* with (a) intravenous sodium bicarbonate 1.4 % (or 154 mmol/l in dextrose 5 % water): 3 ml/kg/h for 1 hour before followed by 1 ml/kg/hr for 4-6 hours after contrast medium or (b) with intravenous saline 0.9 % for 3-4 hours before and 4-6 hours after contrast medium.
- The clinician responsible for patient care should individualize preventive hydration in patients with severe congestive heart failure (NYHA grade 3-4) or patients with end-stage renal failure (eGFR < 15 ml/min/1.73 m²).
- Oral hydration is not recommended as the sole method of preventive hydration.
**EMERGENCY EXAMINATION**

**At-risk patients (see above)**
- Consider an alternative imaging method not using iodine-based contrast media.
- Use preventive hydration before contrast medium administration (see 'Elective examination' for protocols).

**B.2.3. Time of examination**

**All patients**
- Use low- or iso-osmolar contrast media.
- Use the lowest dose of contrast medium consistent with a diagnostic result.
- For intra-arterial contrast medium administration with first pass renal exposure, keep either the ratio CM dose (in gram l) / absolute eGFR (in ml/min) < 1.1 or the ratio CM volume (in ml) / eGFR (in ml/ min/1.73 m²) < 3.0, when using contrast medium concentration of 350 mgl/ml.

**B.2.4. After the Examination**

**At-risk patients**
- Continue preventive hydration if appropriate (see protocols above).
- Determine eGFR 48 hours after contrast medium administration.
- If at 48 hours there is a diagnosis of PC-AKI, monitor the patient clinically for at least 30 days and determine eGFR at regular intervals.

**Note:** No pharmacological prophylaxis (with statins, renal vasodilators, receptor antagonists of endogenous vasoactive mediators or cytoprotective drugs) has been shown to offer consistent protection against PC-AKI.
B.2.5. **Multiple myeloma patients**

- Multiple myeloma patients with normal renal function are not at increased risk of PC-AKI provided that they are well hydrated and that low- or iso-osmolar iodine-based contrast media are used.
- Multiple myeloma patients often have reduced renal function, and such patients are at increased risk of PC-AKI.
- Multiple myeloma patients often have hypercalcemia which can increase the risk of kidney damage. Correction of hypercalcemia before contrast medium administration should be discussed with the hematologist.
- Assessment for Bence Jones proteinuria before contrast medium administration is not necessary.

B.3. **RENAL ADVERSE REACTIONS TO GADOLINIUM-BASED CONTRAST MEDIA**

**MR-EXAMINATIONS**

- The risk of PC-AKI is very low when gadolinium-based contrast agents are used in approved doses.
- In patients with reduced renal function refer to ESUR guidelines on NSF, A.3.2.

**RADIOGRAPHIC EXAMINATIONS**

- Gadolinium-based contrast agents are not approved for radiographic examinations.
- Gadolinium-based contrast agents should not be used for radiographic examinations in patients with renal impairment (eGFR < 60 ml/min/1.73 m²).
- Gadolinium-based contrast agents are more nephrotoxic than iodine-based contrast media in equivalent X-ray attenuating doses.
B.4. PATIENTS WITH DIABETES MELLITUS TAKING METFORMIN

B.4.1. Iodine-based contrast media

1. Patients with eGFR > 30 ml/min/1.73 m² and no evidence of AKI, receiving either intravenous contrast medium or intra-arterial contrast medium with second pass renal exposure: continue taking metformin normally.

2. Patients
   (a) with eGFR < 30 ml/min/1.73 m² receiving intravenous contrast medium, or intra-arterial contrast medium with second pass renal exposure.
   (b) Receiving intra-arterial contrast medium with first pass renal exposure.
   (c) With AKI: Stop taking metformin from the time of contrast medium administration. Measure eGFR within 48 hours and restart metformin if renal function has not changed significantly.

B.4.2. Gadolinium-based contrast media

No special precautions are necessary when diabetic patients on metformin are given gadolinium-based contrast agents as the risk of PC-AKI is very low.
### B.5. DIALYSIS AND CONTRAST MEDIUM ADMINISTRATION

All iodine- and gadolinium-based contrast agents can be removed by hemodialysis or peritoneal dialysis. **However, there is no evidence that hemodialysis protects patients with impaired renal function from post contrast acute kidney injury or nephrogenic systemic fibrosis.**

In all patients, avoid osmotic and fluid overload. To avoid the risk of NSF refer to A.3.2.

#### PATIENTS ON DIALYSIS

<table>
<thead>
<tr>
<th>Patients on hemodialysis</th>
<th>Iodine-based contrast medium</th>
</tr>
</thead>
<tbody>
<tr>
<td>Correlation of time of the contrast medium injection with the hemodialysis session is unnecessary.</td>
<td></td>
</tr>
<tr>
<td>Extra hemodialysis session to remove contrast medium is unnecessary.</td>
<td></td>
</tr>
</tbody>
</table>

**Gadolinium-based contrast agent**

- Correlation of time of the contrast agent injection with the hemodialysis session is recommended.
- Extra hemodialysis session to remove contrast agent as soon as possible after it has been administered is recommended.

<table>
<thead>
<tr>
<th>Patients on continuous ambulatory peritoneal dialysis</th>
<th>Iodine-based contrast medium</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemodialysis to remove the contrast medium is unnecessary.</td>
<td></td>
</tr>
</tbody>
</table>

**Gadolinium-based contrast agent**

The need for hemodialysis should be discussed with the referring physician.
B.6. CAN IODINE- AND GADOLINIUM-BASED CONTRAST AGENTS SAFELY BE GIVEN ON THE SAME DAY FOR ROUTINE EXAMINATIONS?

Efficient practice may involve giving iodine- and gadolinium-based contrast agents for enhanced CT and MR on the same day. To reduce any potential for nephrotoxicity the following are recommended:

1. **Patients with normal renal function or moderately reduced (GFR > 30 ml/min/1.73 m²).**
   75% of both gadolinium- and iodine-based contrast agents are excreted by 4 hours after administration. There should be 4 hours between injections of iodine- and gadolinium-based contrast agents.

2. **Patients with severely reduced renal function (GFR < 30 ml/min/1.73 m² or on dialysis).**
   There should be 7 days between injections of iodine- and gadolinium-based contrast agents.

**Note:** Gadolinium-based contrast agents attenuate X-rays well and may be misinterpreted on CT when they have been excreted into the urinary tract. For abdominal examinations, enhanced CT should be done before enhanced MR. For chest and brain examinations, either CT or MR may be done first.
B.7. **HOW LONG SHOULD THERE BE BETWEEN TWO IODINE-BASED CONTRAST MEDIUM INJECTIONS FOR ROUTINE EXAMINATIONS?**

1. **Patients with normal or moderately reduced renal function (GFR > 30 ml/min/1.73 m²).**
   
   75% of iodine-based contrast medium is excreted by 4 hours after administration. There should be 4 hours between injections of iodine-based contrast medium.

2. **Patients with severely reduced renal function (GFR < 30 ml/min/1.73 m²).**
   
   There should be 48 hours between injections of iodine-based contrast medium.

3. **Patients on dialysis.**
   
   If there is remnant renal function there should be at least 48 hours between injections of iodine-based contrast medium.

B.8. **HOW LONG SHOULD THERE BE BETWEEN TWO GADOLINIUM-BASED CONTRAST AGENT INJECTIONS FOR ROUTINE EXAMINATIONS?**

1. **Patients with normal or moderately reduced renal function (GFR > 30 ml/min/1.73 m²).**
   
   75% of extracellular gadolinium-based contrast agents are excreted by 4 hours after administration.
   
   There should be 4 hours between injections of gadolinium-based contrast agent.

2. **Patients with severely reduced renal function (GFR < 30 ml/min/1.73 m²) or on dialysis.**
   
   There should be 7 days between injections of gadolinium-based contrast agent.
### C. MISCELLANEOUS

#### C.1. CONTRAST MEDIUM EXTRAVASATION

| Type of injuries | • Most injuries are minor.  
|                 | • Severe injuries include skin ulceration,  
|                 | soft-tissue necrosis, and compartment  
|                 | syndrome. |

<table>
<thead>
<tr>
<th><strong>RISK FACTORS</strong></th>
<th></th>
</tr>
</thead>
</table>
| **Technique-related** | • Use of a power injector.  
|                  | • Less optimal injection sites including lower  
|                  | limb and small distal veins.  
|                  | • Large volume of contrast medium.  
|                  | • High-osmolar contrast media.  
|                  | • High-viscosity contrast media. |
| **Patient-related** | • Inability to communicate.  
|                 | • Fragile or damaged veins.  
|                 | • Arterial insufficiency.  
|                 | • Compromised lymphatic and/or venous  
|                 | drainage.  
|                 | • Obesity.  |

| **To reduce the risk** | • Intravenous technique should always be  
|                       | meticulous using an appropriate sized plastic  
|                       | cannula placed in a suitable vein to handle  
|                       | the flow rate used during the injection.  
|                       | • Consider use of cannulas with sideholes.  
|                       | • Test injection with normal saline.  
|                       | • Use non-ionic iodine-based contrast  
|                       | medium. |

| **Management** | • Documenting the extravasation with a plain  
|               | radiograph, CT scan or MR scan of the  
|               | affected region may be helpful.  
|               | • Conservative management is adequate  
|               | in most cases.  
|               | • Limb elevation  
|               | • Ice packs  
|               | • Careful monitoring.  
|               | • If a serious injury is suspected, seek the  
|               | advice of a surgeon. |
C.2. PULMONARY EFFECTS OF IODINE-BASED CONTRAST MEDIA

| Pulmonary adverse effects                        | • Bronchospasm.  
|                                               | • Increased pulmonary vascular resistance.  
|                                               | • Pulmonary edema.  
| Patients at high risk                          | • History of asthma.  
|                                               | • History of pulmonary hypertension.  
|                                               | • Incipient cardiac failure.  
| To reduce the risk of pulmonary adverse effects| • Use low- or iso-osmolar contrast media.  
|                                               | • Avoid large doses of contrast media.  

C.3. EFFECTS OF CONTRAST MEDIA ON BLOOD AND ENDOTHELIOUM

C.3.1. Thrombosis

C.3.1.1. Iodine-based contrast media

The clinically important adverse effect of iodine-based contrast media on blood and endothelium is thrombosis. It is recognized that:

- All contrast media have anticoagulant properties, especially ionic agents.
- High-osmolar ionic contrast media may induce thrombosis due to endothelial damage, particularly in phlebographic procedures.
- Drugs and interventional devices that decrease the risk of thromboembolic complications during interventional procedures minimize the importance of the effects of contrast media.

Guidelines

- Meticulous angiographic technique is mandatory and is the most important factor in reducing thromboembolic complications.
- Low- or iso-osmolar contrast media should be used for diagnostic and interventional angiographic procedures including phlebography.
C.3.2. Sickle Cell Disease

C.3.2.1. Iodine-based contrast media

- In patients with sickle cell disease, high-osmolar iodine-based contrast media may cause red cell sickling, leading to hemolysis and small vessel occlusion.
- Low- or iso-osmolar iodine-based contrast media produce no more adverse events in patients with sickle cell disease than in the normal population.

Guidelines
- Use low- or iso-osmolar iodine-based contrast media.
- Hydrate patients before contrast medium administration.

C.3.2.2. Gadolinium-based contrast media

- The smaller doses of gadolinium-based contrast agents compared to iodine-based contrast media reduce the osmolar load, so contrast agent osmolality is unlikely to be a significant problem.
- No adverse events suggestive of red blood cell sickling have been reported after gadolinium-based contrast agents.

Guidelines
- Use any gadolinium-based contrast agent.
- No special preparation is necessary.

C.4. CONTRAST AGENTS AND CATECHOLAMINE PRODUCING TUMORS (PHEOCHROMOCYTOMA AND PARAGANGLIOMA)

Preparation
a) Before intravenous iodine- or gadolinium-based contrast agent: no special preparation is required.
b) Before intra-arterial iodine-based contrast medium: α and β-adrenergic blockade with orally administered drugs under the supervision of the referring physician is recommended.

Type of contrast agent which should be used
- Iodine-based: non-ionic agent.
- Gadolinium-based: any agent.
## C.5. PREGNANCY AND LACTATION

<table>
<thead>
<tr>
<th></th>
<th>Iodine-based contrast media</th>
<th>Gadolinium-based contrast agents</th>
</tr>
</thead>
</table>
| **Pregnancy**       | a) In exceptional circumstances, when radiographic examination is essential, iodine-based contrast media may be given to the pregnant female.  
|                     | b) Following administration of iodine-based contrast media to the mother during pregnancy, thyroid function should be checked in the neonate during the first week. | a) When there is a very strong indication for enhanced MR, the smallest possible dose of a macrocyclic gadolinium contrast agent (see A.3.2. Agents with lowest risk of NSF) may be given to the pregnant female.  
|                     | b) Following administration of gadolinium-based agents to the mother during pregnancy, no neonatal tests are necessary. |
| **Lactation**       | Breast feeding may be continued normally when iodine-based contrast media is given to the mother. | Breast feeding may be continued normally when macrocyclic gadolinium-based contrast agents are given to the mother. |
| **Pregnant or lactating mother with renal impairment** | See renal adverse reactions (B.2.). No additional precautions are necessary for the fetus or neonate. | Do not administer gadolinium-based contrast agents. |
### C.6. INTERACTION WITH OTHER DRUGS AND CLINICAL TESTS

**General recommendation**  
Be aware of the patient’s drug history.  
Keep a proper record of the contrast agent injection (time, dose, name).  
Do not mix contrast agents with other drugs in tubes and syringes.

**Drugs needing special attention**

<table>
<thead>
<tr>
<th>Metformin</th>
<th>Refer to renal adverse reactions section (B.4.).</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Nephrotoxic drugs</strong></td>
<td>Stopping nephrotoxic drugs before administering contrast agents is not generally recommended.</td>
</tr>
<tr>
<td>Cyclosporine</td>
<td></td>
</tr>
<tr>
<td>Cisplatin</td>
<td></td>
</tr>
<tr>
<td>Aminoglycosides</td>
<td></td>
</tr>
<tr>
<td>Non steroid anti-inflammatory drugs</td>
<td></td>
</tr>
</tbody>
</table>

**ß-blocker**  
ß-blockers may impair the management of bronchospasm and the response to adrenaline.

**Interleukin-2**  
Refer to late adverse reactions section (A.2.).

**Non-emergency biochemical assays**

**Recommendation**  
- Preferably collect urine and blood before administration of a contrast agent.  
- In patients with normal renal function, blood can be collected 4 hours after contrast agent administration if necessary.  
- In patients with reduced renal function (eGFR < 45 ml/min/1.73 m²), blood collection should be delayed for as long as possible after contrast agent administration.  
- Urine collection should not be done within 24 hours of administration of a contrast agent.  
- The effects of the contrast agents on the analyses may differ dependent on which analytic method is used.

**Isotope studies and/or treatment**

**Thyroid**  
Patients undergoing therapy with radioactive iodine should not have received iodine-based contrast medium for at least 2 months before treatment.  
Isotope imaging of the thyroid should be avoided for 2 months after iodine-based contrast medium injection.

**Bone, red blood cell labelling**  
Avoid iodine-based contrast medium injection for at least 24 hours before the isotope study.
C.7. GADOLINIUM ISSUES

C.7.1. Gadolinium retention in the brain

C.7.1.1. Detection

- Seen as regions of increased signal intensity in the deep brain nuclei on unenhanced T1-weighed MR-images.
- The association between these appearances and gadolinium-based contrast agents was first noted in 2014.

C.7.1.2. Characteristics

- The signal intensity changes are not specific and may occur after manganese, iron, calcium etc.
- MR is less sensitive for detecting gadolinium in the brain than tissue analysis after biopsy.
- It is not known whether the deposited gadolinium is chelated.
- No neurological symptoms have yet been reported.
- The clinical significance of these changes is not yet known.
- All studies have been retrospective.
- Occurs independent of renal function.

C.7.1.3. Relation to gadolinium-based agents

- High signal intensity in the deep brain nuclei on MRI has been reported after all linear gadolinium-based agents, but not after macrocyclic agents.
- Analysis of brain tissue has detected gadolinium after all gadolinium-based agents with the highest levels of gadolinium in patients who had linear chelates and the lowest levels in those who had macrocyclic agents.
- The greater the previous cumulative dose of the gadolinium-based agent, the more widespread are the areas of increased signal intensity.
- Only occurs after multiple doses.
C.72. Gadolinium retention in bone, liver and skin

C.72.1. Detection

• Requires biopsy and tissue analysis.

C.72.2. Characteristics

• Occurs independent of renal function.
• May occur after any agent but greater amounts are retained after non-ionic linear agents.
• Cannot be detected by MRI.
• The amounts deposited are small but greater than in the brain.
• Bone and liver retention do not produce clinical symptoms.
• Skin deposition causes red skin plaques similar to those seen in NSF.
• Apart from NSF, the clinical consequences of bone, liver and skin deposition are unknown.

C.73. Gadolinium contamination of the environment

• Use of gadolinium-based contrast agents for MRI has led to gadolinium reaching the environment in waste water.
• At present the amounts of gadolinium in surface and tap water are very low but they are likely to increase with increasing use of gadolinium-based contrast agents.
• The risks of this gadolinium in the environment are not yet known but there is concern that it might contribute to gadolinium deposition in human tissues.
• Monitoring of gadolinium level in the water and better water purification using reverse osmosis membranes are needed to reduce the potential for harm (see Acta Radiol 2017, 58: 259-263).
## C.8. SAFETY OF ULTRASOUND CONTRAST AGENTS

| **Statements** | • Ultrasound contrast agents are generally safe.  
| | • Clinical evidence of ultrasound contrast agent related events in critically ill patients and patients with acute coronary disease is limited. |
| **Contraindication** | • Avoid ultrasound contrast agents in the 24 hours before extracorporeal shock wave treatment. |
| **Type and severity of reactions** | • The majority of reactions are minor (e.g. headache, nausea, sensation of heat, altered taste) and self-resolving.  
| | • More severe acute reactions are rare and are similar to those after iodine- and gadolinium-based agents (see A.1.). |
| **To reduce the risk** | • Check for intolerance to any of the components of the contrast agent.  
| | • Use the lowest level of acoustic output and shortest scanning time to allow a diagnostic examination. |
| **Treatment** | • If a serious event occurs – see General adverse reaction section A.1.2. |
## C.9. SAFETY OF BARIUM CONTRAST MEDIA

<table>
<thead>
<tr>
<th>Statements</th>
<th>Recommended action</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Contraindications</strong></td>
<td></td>
</tr>
<tr>
<td>Integrity of gut wall compromised</td>
<td>Use iodine-based water-soluble contrast media. In neonates and patients at risk of leakage into mediastinum and/or lungs use low- or iso-osmolar contrast media.</td>
</tr>
<tr>
<td>Previous allergic reactions to barium products</td>
<td>Use iodine-based water-soluble contrast media and be prepared to treat a reaction.</td>
</tr>
<tr>
<td><strong>Cautions</strong></td>
<td></td>
</tr>
<tr>
<td>Bowel strictures</td>
<td>Use only small amounts.</td>
</tr>
<tr>
<td>Extensive colitis</td>
<td>Avoid barium enemas.</td>
</tr>
<tr>
<td><strong>Complications</strong></td>
<td></td>
</tr>
<tr>
<td>Reduced bowel motility</td>
<td>Encourage fluid intake.</td>
</tr>
<tr>
<td>Venous intravasation</td>
<td>• Early identification and careful observation.</td>
</tr>
<tr>
<td></td>
<td>• Antibiotics and intravenous fluids.</td>
</tr>
<tr>
<td></td>
<td>• Emergency treatment may be needed.</td>
</tr>
<tr>
<td>Aspiration</td>
<td>• Bronchoscopic removal for large amounts.</td>
</tr>
<tr>
<td></td>
<td>• Chest physiotherapy.</td>
</tr>
<tr>
<td></td>
<td>• Antibiotics.</td>
</tr>
</tbody>
</table>
C.10. PEDIATRIC USE OF CONTRAST AGENTS

- Safety considerations when using contrast media in neonates, infants and children are similar to, but not the same as, in adults.
- Contrast agent dose must be adjusted for patient age and weight.
- Age-specific normal values of serum creatinine etc. must be used.
- The revised Schwartz equation is recommended to measure eGFR (see B.1.).
- For iodine-based contrast media, non-ionic agents should be used.
- For gadolinium-based contrast agents, high-risk agents should be avoided.
- The Summary of Product Characteristics for the contrast agent should be consulted, because not all contrast agents are approved for use in children.
- If no suitable contrast agent approved for use in children is available, informed consent for off-label use must be obtained from the parents. However, if use of a specific contrast agent in children is absolutely contra-indicated, it may not be used, even with informed consent.

C.11. OFF-LABEL USE OF CONTRAST AGENTS

- Off-label use of diagnostic and therapeutic medication is common.
- The Summary of Product Characteristics (SPC) or label should be checked to see if the proposed contrast agent use is approved for the particular patient and indication.
- Choose a contrast agent which is approved for the particular patient and indication whenever possible.
- If there is no suitable approved contrast medium, the prescriber must tell the patient about the risks and benefits of off-label contrast agent use, and must obtain the patient’s informed consent to off-label contrast agent administration.
D. QUESTIONNAIRES/LETTERS

D.1. AN EXAMPLE OF A SUITABLE LETTER FOR THE PATIENT TO TAKE TO THE ALLERGY CONSULTATION

Dear colleague,

(Insert patient’s name and details) had a hypersensitivity reaction after the administration of a contrast agent on (insert date).

Examination type (e.g. CT, MRI, IV…..):

Type of contrast agent:

- O iodine-based
- O gadolinium-based
- O ultrasound

Name of the contrast agent:

Dose administered: .............................................ml

Route of administration (e.g. IV, IA, intra-articular, oral, local…….):

Time between the injection and the start of the clinical symptoms:

Type of symptoms (describe):
Grade of the reaction according to the Ring and Messmer classification:

<table>
<thead>
<tr>
<th>Grade</th>
<th>Dermal</th>
<th>Abdominal</th>
<th>Respiratory</th>
<th>Cardiovascular</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Pruritus, Flushing, Urticaria, Angioedema</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Pruritus, Flushing, Urticaria, Angioedema</td>
<td>Nausea, Cramping</td>
<td>Rhinorrhea, Hoarseness, Dyspnea</td>
<td>Tachycardia (&gt; 20 bpm), Blood pressure change (&gt; 20 mm Hg systolic), Arrhythmia</td>
</tr>
<tr>
<td>3</td>
<td>Pruritus, Flushing, Urticaria, Angioedema</td>
<td>Vomiting, Defecation, Diarrhea</td>
<td>Laryngeal edema, Bronchospasm, Cyanosis</td>
<td>Shock</td>
</tr>
<tr>
<td>4</td>
<td>Pruritus, Flushing, Urticaria, Angioedema</td>
<td>Vomiting, Defecation, Diarrhea</td>
<td>Respiratory arrest</td>
<td>Cardiac arrest</td>
</tr>
</tbody>
</table>

Treatment given during the reaction:
- (please specify)

Outcome (e.g. follow up, ICU, return home .......):
- Histamine and/or Tryptase blood tests:

Blood test performed at the time of the reaction
YES/NO 2 HRS LATER YES/NO

Results: Histamine: Tryptase: 

PREVIOUS HISTORY OF CONTRAST AGENT REACTION
- Yes/No
- If yes, please specify type of contrast agent and symptoms

Thank you for seeing the patient and performing skin testing to categorize the reaction as either allergic or non-allergic hypersensitivity, and to look for cross-reactivity so that a safer contrast agent can be recommended for future injections.

Your sincerely,
Dr (Name and details)
# D.2. QUESTIONNAIRE FOR IODINE-BASED CONTRAST MEDIA ADMINISTRATION TO BE COMPLETED BY THE REFERRING CLINICIAN

<table>
<thead>
<tr>
<th></th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. History of moderate or severe reaction to an iodine-based contrast medium</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. History of atopy requiring treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. History of unstable asthma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Hyperthyroidism</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Heart failure</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Diabetes mellitus</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. History of renal disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8. Previous renal surgery</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9. History of proteinuria</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10. Hypertension</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11. Gout</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12. Most recent measurement of serum creatinine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Value</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Date</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13. Is the patient currently taking any of the following drugs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Metformin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Interleukin 2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• NSAIDs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Aminoglycosides</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• ß-blockers</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Completed by _______________________ Date _____________________
### D.3. QUESTIONNAIRE FOR GADOLINIUM-BASED CONTRAST AGENT ADMINISTRATION TO BE COMPLETED BY THE REFERRING CLINICIAN

<table>
<thead>
<tr>
<th></th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>History of moderate or severe reaction to a gadolinium-based contrast medium</td>
<td>☐</td>
</tr>
<tr>
<td>2.</td>
<td>History of atopy requiring treatment</td>
<td>☐</td>
</tr>
<tr>
<td>3.</td>
<td>History of unstable asthma</td>
<td>☐</td>
</tr>
<tr>
<td>4.</td>
<td>Has the patient end-stage renal failure (eGFR &lt; 30 ml/min/1.73m²) or is the patient on dialysis</td>
<td>☐</td>
</tr>
<tr>
<td>5.</td>
<td>Has the patient reduced renal function* (eGFR between 30 and 60 ml/min/1.73 m²)</td>
<td>☐</td>
</tr>
</tbody>
</table>

* Only if high-risk agents are used

Completed by _______________________ Date _____________________
Appendix 1. Publications from the ESUR Contrast Media Safety Committee


Thomsen HS, Morcos SK, Members of Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR). In which patients should serum-creatinine be measured before contrast medium administration? Eur Radiol 2005; 15: 749–754.


Appendix 2. Contrast Media Safety Committee - Spring 2018

Henrik S. Thomsen (DK) **Chairman**
Fulvio Stacul (IT) **Secretary**
Marie-France Bellin (FR)
Michele Bertolotto (IT)
Georg Bongartz (CH)
Torkel Brismar (SE)
Olivier Clement (FR)
Jean-Michel Correas (FR)
Remy W. F. Geenen (NL)
Gertraud Heinz-Peer (AT)
Andreas H. Mahnken (DE)
Alexander Radbruch (DE)
Peter Reimer (DE)
Giles Roditi (UK)
Laura Romanini (IT)
Aart J. van der Molen (NL)
Judith A.W. Webb (UK)

**Corresponding member**
Claudio Ronco (IT)

**Consultants**
Thomas Balzer (Bayer, DE)
Eric Lancelot (Guerbet, FR)
Alberto Spinazzi (Bracco, IT)